F. Nelson

发表

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

R. D. Williams, W. Hoffman, F. Menniti, 2008, Journal of Pharmacology and Experimental Therapeutics.

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice

F. Nelson, B. Feng, Lin Zhou, 2009, Drug Metabolism and Disposition.

The Effect of Breast Cancer Resistance Protein ( Bcrp ) and P-glycoprotein ( Mdr 1 a / 1 b ) on the Brain Penetration of Flavopiridol , Gleevec , Prazosin and PF-407288 in Mice

F. Nelson, B. Feng, Lin Zhou, 2009 .

Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.

F. Nelson, D. Raunig, K. Schmidt, 2010, Journal of veterinary pharmacology and therapeutics.

Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

Tracy M. Brown, F. Nelson, T. Lanz, 2008, Biochemical pharmacology.

Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools

D. B. Duignan, F. Nelson, R. Obach, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

In Vitro Stability and In Vivo Pharmacokinetics of the Novel Ketogenic Ester, Bis Hexanoyl (R)-1,3-Butanediol.

F. Nelson, E. Verdin, John C Newman, 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

K. Fennell, J. Pandit, F. Menniti, 2011, Journal of medicinal chemistry.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Spiros Liras, Anne W. Schmidt, J. Pandit, 2009, Journal of medicinal chemistry.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

F. Menniti, F. Nelson, C. Proulx-Lafrance, 2012, Journal of medicinal chemistry.

Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration

J. Cianfrogna, F. Nelson, Xingrong Liu, 2006, Drug Metabolism and Disposition.

Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors

R. Volkmann, F. Menniti, F. Nelson, 2020, Neuropharmacology.

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Xi Chen, Karthik Venkatakrishnan, Matthew Troutman, 2005, Drug Metabolism and Disposition.

PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers

B. Corrigan, H. Soares, T. Nicholas, 2009, Alzheimer's & Dementia.

An Inhibitor of Casein Kinase Iϵ Induces Phase Delays in Circadian Rhythms under Free-Running and Entrained Conditions

Eric Schaeffer, Robin Kleiman, Katherine Fisher, 2007, Journal of Pharmacology and Experimental Therapeutics.

P-Glycoprotein Contributes to the Blood-Brain, but Not Blood-Cerebrospinal Fluid, Barrier in a Spontaneous Canine P-Glycoprotein Knockout Model

F. Nelson, K. Schmidt, K. Mealey, 2008, Drug Metabolism and Disposition.

Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).

Jiri Aubrecht, Scot Mente, Jennifer B Munzner, 2011, Journal of medicinal chemistry.

Selective Brain Penetrant PDE 9 A Inhibitor for the Treatment of Cognitive Disorders

Ey, F. Menniti, F. Nelson, 2012 .

Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures

F. Nelson, K. Venkatakrishnan, M. Gibbs, 2007, Drug Metabolism And Disposition.

Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

Ernesto Callegari, Bill J Smith, J. Cianfrogna, 2005, Journal of Pharmacology and Experimental Therapeutics.

An inhibitor of casein kinase I epsilon induces phase delays in circadian rhythms under free-running and entrained conditions.

Eric Schaeffer, Robin Kleiman, Katherine Fisher, 2007, The Journal of pharmacology and experimental therapeutics.

Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Anne W. Schmidt, F. Menniti, F. Nelson, 2009, Journal of medicinal chemistry.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Laura McDowell, Spiros Liras, Mihaly Hajos, 2012, Journal of medicinal chemistry.